FDA Panel Unanimously Supports Luxturna Gene Therapy

October 13, 2017

An FDA advisory panel unanimously backed Spark Therapeutics Luxturna gene therapy for inherited retinal diseases. The one time treatment will be the first gene therapy approved for inherited disease in the USA. Read the full story from Market Scope.





Share on Facebook
Share on Twitter
Please reload

Featured Review

Leadership Development for Women in STEM

September 21, 2019

Please reload

Tag Cloud

© 2017 by eyebytes 

  • Facebook Social Icon
  • LinkedIn Social Icon
  • Twitter Social Icon
  • Instagram Social Icon
This site was designed with the
website builder. Create your website today.
Start Now